Compare GSK plc (GSK) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Verisign, Inc. — how do they compare? GSK plc trades at $52.73 (market cap $101.34B), while Verisign, Inc. trades at $276.78 (market cap $24.62B). The key difference: GSK plc is far larger — about 4.1× Verisign, Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | VRSN | |
|---|---|---|
Market Cap | $101.34B | $24.62B |
Sector | Health | Technology |
52-Week High | $61.18 | $310.00 |
52-Week Low | $36.20 | $211.49 |
Enterprise Value | $121.95B | $25.86B |
Dividend Yield | 3.49% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VeriSign (VRSN) trades at $268.85, down 0.54% today, with a bullish technical outlook and strong fundamentals. The stock shows consistent revenue growth, reaching $1.66B in 2025, and maintains high profit margins near 50%. Recent Q1 2026 earnings beat expectations at $2.34 EPS, though Q4 2025 missed. Analyst consensus is bullish with a $325.25 price target, and technical indicators suggest support at $265 with resistance at $271.
VRSN offers stable growth driven by its monopoly on .com and .net domains, but faces risks from AI disruption and contract renewals. The stock is fairly valued with a P/E of 29.89, and institutional sentiment is positive. Key risks include high debt levels and competitive threats, yet the company's cash flow and dividend payments support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
